A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma

Project: Research

Project Details

Effective start/end date24/01/2023/01/25


  • clinical trial
  • treatment efficacy
  • treatment safety
  • liver cancer
  • phase 3 study